| [1] | Journal of Hepatology｜Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1[J]. Journal of Clinical Hepatology, 2024, 40(3): 508-508. doi: 10.12449/JCH2403.gwqkjpwzjj1 |
| [2] | Teng LIU, Xiujuan CHANG, Quanwei HE, Ran XU, Yongping YANG. Efficacy and safety of cryoablation combined with lenvatinib and anti-PD-1 monoclonal antibody in treatment of unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(3): 539-549. doi: 10.12449/JCH240317 |
| [3] | Qiuju PENG, Tao DAI, Guibo XIE, Jinjun CHEN, Xiao CHENG, Yuan YAN. Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(7): 1740-1746. doi: 10.3969/j.issn.1001-5256.2023.07.033 |
| [4] | Journal of Gastroenterology and Hepatology｜Compared with chemotherapy alone as the first-line treatment, PD-1 inhibitor combined with chemotherapy can significantly improve the median progression-free survival time of patients with metastatic or recurrent cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(2): 401-401. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj5 |
| [5] | Journal of Hepatology｜Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity[J]. Journal of Clinical Hepatology, 2022, 38(4): 890-890. doi: 10.3969/j.issn.1001-5256.2022.04.gwjpwzjj2 |
| [6] | Journal of Gastroenterology and Hepatology｜Rifampicin can improve cholestasis in patients with persistent hepatocellular secretory failure[J]. Journal of Clinical Hepatology, 2022, 38(2): 396-396. doi: 10.3969/j.issn.1001-5256.2022.02.gwjpwzjj4 |
| [7] | Haonan LIU, Yuqin WANG, Meng WU, Tong LU, Yang ZHAO, Zhengxiang HAN. Effectiveness and safety of programmed cell death-1 inhibitor in the treatment of advanced non-HBV non-HCV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(12): 2761-2766. doi: 10.3969/j.issn.1001-5256.2022.12.015 |
| [8] | Dazhi LI, Junjie HUANG, Shusen ZHENG, Aibin ZHANG. Role of thioredoxin reductase 1 in multidrug resistance caused by reactive oxygen species-related cell apoptosis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(2): 372-380. doi: 10.3969/j.issn.1001-5256.2022.02.022 |
| [9] | Xin DAI, Hanlin LIU, Long CHENG, Zhulin LUO, Tao WANG. Association of programmed death-1 and programmed death-ligand 1 with the prognosis and clinical features of patients with hepatocellular carcinoma: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1577-1583. doi: 10.3969/j.issn.1001-5256.2022.07.022 |
| [10] | Xiaopeng DING, Jun TIE, Jiahao YU, Pengwei REN, Guoyun XUAN, Shuoyi MA, Changcun GUO, Ying HAN, Xinmin ZHOU. Efficacy and safety of programmed death-1 inhibitor combined with transarterial chemoembolization and anti-angiogenic drugs in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1086-1091. doi: 10.3969/j.issn.1001-5256.2022.05.021 |
| [11] | Ying TENG, Xiaoyan DING, Wendong LI, Jinglong CHEN. Clinical effect of programmed cell death-1 inhibitor combined with lenvatinib in treatment of advanced primary liver cancer and related adverse events[J]. Journal of Clinical Hepatology, 2021, 37(3): 606-610. doi: 10.3969/j.issn.1001-5256.2021.03.020 |
| [12] | Zhaoyue WANG, Lai WEI, Yuan HUANG. Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 437-443. doi: 10.3969/j.issn.1001-5256.2021.02.040 |
| [13] | Yuchen FEI, Donglai LYU. Anti-PD-1 monoclonal antibody combined with apatinib in treatment of rare primary squamous cell carcinoma of the liver: A case report[J]. Journal of Clinical Hepatology, 2021, 37(3): 670-672. doi: 10.3969/j.issn.1001-5256.2021.03.032 |
| [14] | Song XUE, Gaobo HUANG, Xiaofei YANG, Ye ZHANG, Yu LI. Influence of interleukin-6 on the expression and function of programmed death-1 in CD8+ T cells from patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(10): 2332-2337. doi: 10.3969/j.issn.1001-5256.2021.10.015 |
| [15] | Ha FuShuang, Han Tao, Tang Fei, Yan JunQing, Wang HaoYu. Predictive factors for the clinical effect of PD-1/PD-L1 checkpoint inhibitors in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1389-1392. doi: 10.3969/j.issn.1001-5256.2020.06.044 |
| [16] | Feng GuoYing, Shi ZhengRong. Value of programmed cell death ligand 1 and soluble programmed cell death ligand 1 in predicting the prognosis of hepatocellular carcinoma and related controversies[J]. Journal of Clinical Hepatology, 2020, 36(8): 1858-1861. doi: 10.3969/j.issn.1001-5256.2020.08.039 |
| [17] | ZHOU Ge, XIE LiPing, LIN TaoFa, LU YouGuang, WANG ShaoYang. Expression and significance of programmed death-1 and T-cell immunoglobulin-and mucin domain-3-containing molecule 3 in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(11): 2450-2455. doi: 10.3969/j.issn.1001-5256.2020.11.011 |
| [18] | Kong LingBo, Nan YueMin, Zhang YuGuo, Zhao SuXian, Wang RongQi, Fu Na, Di HaiLing, Su ShanShan. Association of programmed cell death-1 gene polymorphisms with chronic hepatitis C virus infection and antiviral effect[J]. Journal of Clinical Hepatology, 2016, 32(9): 1721-1724. doi: 10.3969/j.issn.1001-5256.2016.09.017 |
| [19] | Yang Liu, Zhu XiLing, Li Gong. Expression of programmed death-ligand 1 in hepatocellular carcinoma and its clinical significance[J]. Journal of Clinical Hepatology, 2016, 32(8): 1630-1634. doi: 10.3969/j.issn.1001-5256.2016.08.047 |
| [20] | Zhou ZhenHua, Sun XueHua, Li Man, Zhu XiaoJun, Jin ShuGen, Zhang Xin, Gao YaTing, Gao YueQiu. Effect of kidney-tonifying and spleen-strengthening prescription on PD-1 and PD-L1 expression in HBeAg-positive chronic hepatitis B patients with slightly increased ALT levels[J]. Journal of Clinical Hepatology, 2015, 31(1): 58-62. doi: 10.3969/j.issn.1001-5256.2015.01.013 |
DownLoad: